Search research articles
Contact Us
Filters
Showing results (391-400 of 415) with videos related to
Page
of 42
Sort By:
JCO Precision Oncology
|
December 7, 2020
Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study
Francesco Pantano, Paolo Manca, Grazia Armento, et al.
Cancers
|
May 21, 2020
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study
Alessandro Parisi, Alessio Cortellini, Katia Cannita, et al.
Oncotarget
|
September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
Patrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
The Oncologist
|
February 24, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini, Sebastiano Buti, Daniele Santini, et al.
JAMA Oncology
|
November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study
Caroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Journal for Immunotherapy of Cancer
|
March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Cancer Biology & Therapy
|
November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
Teresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Breast Care (Basel, Switzerland)
|
April 2, 2020
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
Marina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Journal of Hematology & Oncology
|
January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
Alessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Page
of 42
Search research articles
Search
Showing results (391-400 of 415) with videos related to
Sort By:
Page
of 42
JCO Precision Oncology
|
December 7, 2020
Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study
Francesco Pantano, Paolo Manca, Grazia Armento, et al.
Cancers
|
May 21, 2020
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study
Alessandro Parisi, Alessio Cortellini, Katia Cannita, et al.
Oncotarget
|
September 17, 2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
Patrizia Vici, Laura Pizzuti, Andrea Michelotti, et al.
The Oncologist
|
February 24, 2019
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini, Sebastiano Buti, Daniele Santini, et al.
JAMA Oncology
|
November 4, 2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study
Caroline A Nebhan, Alessio Cortellini, Weijie Ma, et al.
Journal for Immunotherapy of Cancer
|
March 1, 2019
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Cancer Biology & Therapy
|
November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
Teresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Breast Care (Basel, Switzerland)
|
April 2, 2020
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
Marina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Journal of Hematology & Oncology
|
January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status
Alessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 19, 2020
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Page
of 42